Dr. Jen Liang Su

Dr. Jen Liang Su |Clyto Access

National Institute of Cancer Research, USA

Editorial Board Member

Expertise: Metabolism dysregulation in cancer metastasis, Function and biosynthesis of non-coding RNA, Protein post-translational modification in cancer progression, Metastasis of cancer cells, Translational research of E1A gene therapy

Dr. Su graduated from National Taiwan Normal University and obtained his PhD in National Taiwan University in 2004. He completed postdoctoral training's at Institute of Toxicology, National Taiwan University, Taipei, Taiwan and M.D. Anderson Cancer Center, The University of Texas, Houston, TX, USA. He is currently an associate investigator of National Institute of Cancer Research at National Health Research Institutes in Taiwan. Dr. Su’s early work explored the role of vascular endothelial growth factor-C (VEGF-C) in human lymphangiogenesis and metastasis of lung adenocarcinoma. He and co-workers are the first to show the VEGF-C/VEGF-R3 axis promotes invasion and metastasis of cancer cells (Cancer Cell. 2006 Mar; 9(3):209-23. and Cancer Cell. 2008 Jun;13(6):557-60.). He has published more than 50 original research papers and review articles in peer-reviewed international journals such as Cancer Cell, The Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine, Hepatology, Proceedings of the National Academy of Sciences of the United States of America, Cancer Research, Oncogene, etc. Recently, the main research interests of Dr. Su’s laboratory include (1) Metabolism dysregulation in cancer metastasis and drug resistance; (2) Function and biosynthesis of non-coding RNA in cancer; (3) Protein post-translational modification in cancer progression. As an expert of cancer biology, Dr. Su has been a reviewer for numerous scientific journals and served as a member of multiple grant review panels.

Related Journals & Conferences :

Current Research and Therapy in Cancer